Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Liver Cancer Drug Pipeline Update 2009 | Jan 2009 | £830 | 100% |
| Liver Cancer Drug Pipeline Update 2011 | Feb 2011 | £830 | 99% |
| Liver Cancer - Pipeline Review H1 2012 |
Jan 2012 | £325 | 99% |
| Liver Cancer Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Dec 2010 | £1,265 | 98% |
| Liver Cancer Drugs | Apr 2010 | £2,500 | 98% |
| Liver Cancer Therapy Area Pipeline Report | Mar 2011 | £945 | 97% |
| Liver Cancer - Pipeline Review Q3 2011 |
Jul 2011 | £315 | 95% |
| Avastin (Liver Cancer) Analysis and Forecasts to 2020 |
Jul 2011 | £1,265 | 95% |
| Stakeholder Opinions: Hepatocellular cancer | Dec 2010 | £2,405 | 94% |
| PrevOnco Analysis and Market Forecasts from 2014 to 2020 |
Jul 2011 | £1,265 | 92% |
| Muparfostat Analysis and Market Forecasts from 2017 to 2020 |
Jul 2011 | £1,265 | 92% |
| Doxorubicin Analysis and Market Forecasts from 2011 to 2020 |
Jul 2011 | £1,265 | 92% |
| Linifanib Assessment and Market Forecasts from 2013 to 2020 |
Jul 2011 | £1,265 | 92% |
| Thalidomide Analysis and Market Forecasts from 2015 to 2020 |
Jul 2011 | £1,265 | 92% |
| ThermoDox Analysis and Market Forecasts from 2012 to 2020 |
Jul 2011 | £1,265 | 92% |
| Tarceva Analysis and Market Forecasts from 2013 to 2020 |
Jul 2011 | £1,265 | 92% |
| Nexavar Analysis and Market Forecasts from 2007 to 2020 |
Jul 2011 | £1,265 | 92% |
| Ramucirumab Analysis and Market Forecasts from 2014 to 2020 |
Jul 2011 | £1,265 | 92% |
| Brivanib Analysis and Market Forecasts from 2013 to 2020 |
Jul 2011 | £1,265 | 92% |
| Avastin (bevacizumab) Analysis and Market Forecasts from 2016 to 2020 |
Jul 2011 | £1,265 | 92% |
| Miripla Analysis and Market Forecasts from 2010 to 2020 |
Jul 2011 | £1,265 | 91% |
| IMMUNOMEDICS, INC – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 85% |
| BioAlliance Pharma SA – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 84% |
| MediGene AG – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 84% |
| Alnylam Pharmaceuticals, Inc – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 84% |
| Commercializing Cancer Vaccines A Decision Support Tool for Optimizing the Pipeline |
Oct 2010 | £1,620 | 83% |
| Commercializing Peptides in Oncology A Decision Support Tool for Optimizing the Pipeline |
Jun 2010 | £2,035 | 83% |
| Hepatocellular Carcinoma - Pipeline Review H1 2012 |
Jan 2012 | £325 | 83% |
| Therapeutic Peptides in Oncology Favorable Conditions But Where to Commercialize? |
May 2009 | £2,940 | 82% |
| Commercializing Peptides in Cancer The Faster Route to Consider Your Options and Position of Others |
Nov 2011 | £2,035 | 82% |
